Allan Pantuck, M.D., M.S., FACS

Associate Professor of Urology at the David Geffen School of Medicine at UCLA, Director of the GU Oncology Program of the UCLA Jonsson Comprehensive Cancer Center, and Director of Translational Research for the UCLA Kidney Cancer Program. Dr. Pantuck is a board-certified Urologist who also completed at UCLA an SUO-accredited Urologic Oncology fellowship and an MSc in Clinical Research. He has ten years of experience in the design and implementation of gene and immune-based clinical trials, and specific expertise in diagnostic, prognostic, and therapeutic applications of CAIX. Dr. Pantuck has written over 200 scientific publications with an emphasis on urologic oncology and has lectured worldwide on topics related to immunotherapy, cancer vaccines, and targeted cancer therapies.

Lisa H. Butterfield, Ph.D.

Director of the Immunologic Monitoring and Cellular Products Laboratory and Associate Professor of Medicine, Surgery and Immunology at the University of Pittsburgh. She has been responsible for preclinical development, cGMP scale-up, clinical translation and immunologic monitoring of cancer vaccines for both melanoma and HCC, based on peptides, adenoviruses and dendritic cells. Dr. Butterfield serves as Director of the Eastern Cooperative Oncology Group Central Immunology Laboratory, as well as Melanoma Committee Lab Liaison. She served on the International Society of Biologic Therapy of Cancer (iSBTc) Scientific Program Committee and Board of Directors, and is on the iSBTc/FDA Biomarkers Taskforce Steering Committee. She also served on the NCI Immune Response Modifier Pathway Prioritization Working Group, and is currently a standing member of the NIH CII study section. Dr. Butterfield holds editorial positions for Cancer Research and the Journal of Immunology.